![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAMSTR |
Gene summary for MAMSTR |
![]() |
Gene information | Species | Human | Gene symbol | MAMSTR | Gene ID | 284358 |
Gene name | MEF2 activating motif and SAP domain containing transcriptional regulator | |
Gene Alias | MASTR | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6ZN01 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284358 | MAMSTR | HCC1_Meng | Human | Liver | HCC | 6.25e-16 | 5.87e-02 | 0.0246 |
284358 | MAMSTR | S014 | Human | Liver | HCC | 1.30e-17 | 5.53e-01 | 0.2254 |
284358 | MAMSTR | S015 | Human | Liver | HCC | 8.51e-16 | 6.70e-01 | 0.2375 |
284358 | MAMSTR | S016 | Human | Liver | HCC | 3.12e-24 | 6.25e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAMSTR | SNV | Missense_Mutation | rs751653467 | c.196N>G | p.Leu66Val | p.L66V | Q6ZN01 | protein_coding | tolerated(0.08) | benign(0.108) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MAMSTR | insertion | In_Frame_Ins | novel | c.1194_1195insAGGAGT | p.Asp398_Leu399insArgSer | p.D398_L399insRS | Q6ZN01 | protein_coding | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | ||
MAMSTR | SNV | Missense_Mutation | novel | c.1105N>A | p.Pro369Thr | p.P369T | Q6ZN01 | protein_coding | deleterious(0.02) | possibly_damaging(0.521) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAMSTR | insertion | In_Frame_Ins | novel | c.1017_1018insAGGATGAAG | p.Ser339_Pro340insArgMetLys | p.S339_P340insRMK | Q6ZN01 | protein_coding | TCGA-VS-A9UI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MAMSTR | insertion | In_Frame_Ins | novel | c.1016_1017insTAACCTTTGTTCGCCCCTCACGATTATCAC | p.Ser339_Pro340insAsnLeuCysSerProLeuThrIleIleThr | p.S339_P340insNLCSPLTIIT | Q6ZN01 | protein_coding | TCGA-VS-A9UI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MAMSTR | SNV | Missense_Mutation | c.167C>T | p.Ala56Val | p.A56V | Q6ZN01 | protein_coding | deleterious_low_confidence(0.02) | benign(0.011) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MAMSTR | SNV | Missense_Mutation | novel | c.157T>G | p.Ser53Ala | p.S53A | Q6ZN01 | protein_coding | tolerated_low_confidence(0.31) | benign(0.018) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
MAMSTR | SNV | Missense_Mutation | c.429N>T | p.Met143Ile | p.M143I | Q6ZN01 | protein_coding | tolerated(0.07) | benign(0.081) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
MAMSTR | SNV | Missense_Mutation | novel | c.269G>T | p.Arg90Met | p.R90M | Q6ZN01 | protein_coding | deleterious_low_confidence(0) | benign(0.276) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MAMSTR | SNV | Missense_Mutation | c.815C>G | p.Pro272Arg | p.P272R | Q6ZN01 | protein_coding | tolerated(0.08) | benign(0.119) | TCGA-F5-6864-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |